Omega-3: where the marketing outran the trials

Omega-3 is a useful case study in reading evidence honestly, because the marketing and the trials point in different directions. For a typical healthy adult, the large, high-quality data is a well-powered null. A Cochrane review of 86 trials and roughly 163,000 people found little or no effect of omega-3 supplements on death or cardiovascular events, rated high-certainty. The VITAL trial’s 1 g/day arm likewise missed its primary endpoint — with a modest lower rate of total heart attacks as a secondary hint, not a headline.

Then there’s REDUCE-IT, the trial the supplement industry loves to cite: a 25% reduction in cardiovascular events. It’s real. But it used a prescription drug (icosapent ethyl) at a 4 g/day dose in a specific population — high-risk, already on statins, with high triglycerides. None of those conditions describe the capsule in a general shopper’s cabinet, and the honest move is to refuse to generalize it.

The practical read

Eating fish a couple of times a week is a perfectly reasonable dietary pattern with a good overall profile. If you don’t eat fish, a modest supplement is low-risk and can fill the dietary gap. What it is not is a proven longevity intervention for the average person — which is exactly why it sits low in the supplement tier, graded on suggestive rather than strong grounds. If you have high triglycerides and cardiovascular risk, the prescription conversation is a real one to have with a clinician.